Łukasz Zapała1, Michał Kunc2, Sumit Sharma3, Rafał Pęksa2, Marta Popęda2,4, Wojciech Biernat2, Piotr Radziszewski3. 1. Clinic of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. lzapala@wum.edu.pl. 2. Department of Pathomorphology, Medical University of Gdansk, 80-214, Gdańsk, Poland. 3. Clinic of General, Oncological and Functional Urology, Medical University of Warsaw, Lindleya 4, 02-005, Warsaw, Poland. 4. Laboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdańsk, 80-211, Gdańsk, Poland.
Abstract
PURPOSE: The study aimed to determine the expression of VISTA and TOX within venous tumor thrombus and primary clear cell renal cell carcinoma (ccRCC) and to assess their prognostic value. METHODS: The study enrolled 82 patients with ccRCC and coexisting venous tumor thrombus treated radically from 2012 to 2019 in two tertiary centers. Tissue microarrays were prepared and stained with respective antibodies. The expression of markers was assessed separately on tumor cells (TCs) and/or tumor-associated immune cells (TAICs). RESULTS: TOX expression was positively correlated with the percentage of VISTA-positive TAICs in venous thrombus (p = 0.011), but not in the primary tumor (p = 0.674). High TOX expression was associated with a higher percentage of PD-L1-positive TAICs in both compartments (p = 0.001, p = 0.011, respectively). Positive expression of VISTA on TAICs was associated with PD-L1 expression on TCs (p = 0.005) and TAICs (p = 0.004) in the primary tumor, and only with PD-L1 on TAICs in thrombus (p = 0.006). The presence of VISTA-positive TAICs in venous thrombus was significantly more common in females (p = 0.034), and positively correlated with metastases (p = 0.028), and tumor necrosis (p = 0.013). The cases with VISTA-positive TAICs in venous tumor thrombi had significantly shorter OS than VISTA-negative cases (p = 0.041). CONCLUSION: For the first time, we demonstrated the expression of VISTA- and TOX-positive TAICs in the venous tumor thrombus. We found the association between immune checkpoint receptors and T cell exhaustion markers in both tumor mass and venous thrombus. Finally, we demonstrated that abundance of VISTA-positive TAICs in venous tumor thrombus correlates with worse outcomes in ccRCC.
PURPOSE: The study aimed to determine the expression of VISTA and TOX within venous tumor thrombus and primary clear cell renal cell carcinoma (ccRCC) and to assess their prognostic value. METHODS: The study enrolled 82 patients with ccRCC and coexisting venous tumor thrombus treated radically from 2012 to 2019 in two tertiary centers. Tissue microarrays were prepared and stained with respective antibodies. The expression of markers was assessed separately on tumor cells (TCs) and/or tumor-associated immune cells (TAICs). RESULTS: TOX expression was positively correlated with the percentage of VISTA-positive TAICs in venous thrombus (p = 0.011), but not in the primary tumor (p = 0.674). High TOX expression was associated with a higher percentage of PD-L1-positive TAICs in both compartments (p = 0.001, p = 0.011, respectively). Positive expression of VISTA on TAICs was associated with PD-L1 expression on TCs (p = 0.005) and TAICs (p = 0.004) in the primary tumor, and only with PD-L1 on TAICs in thrombus (p = 0.006). The presence of VISTA-positive TAICs in venous thrombus was significantly more common in females (p = 0.034), and positively correlated with metastases (p = 0.028), and tumor necrosis (p = 0.013). The cases with VISTA-positive TAICs in venous tumor thrombi had significantly shorter OS than VISTA-negative cases (p = 0.041). CONCLUSION: For the first time, we demonstrated the expression of VISTA- and TOX-positive TAICs in the venous tumor thrombus. We found the association between immune checkpoint receptors and T cell exhaustion markers in both tumor mass and venous thrombus. Finally, we demonstrated that abundance of VISTA-positive TAICs in venous tumor thrombus correlates with worse outcomes in ccRCC.
Authors: Y Fujisawa; K Yoshino; A Otsuka; T Funakoshi; T Fujimura; Y Yamamoto; H Hata; R Tanaka; K Yamaguchi; Y Nonomura; I Hirai; S Furudate; H Okuhira; K Imafuku; M Aoki; S Matsushita Journal: Br J Dermatol Date: 2018-04-24 Impact factor: 9.302
Authors: Stephen J Bagley; Shawn Kothari; Charu Aggarwal; Joshua M Bauml; Evan W Alley; Tracey L Evans; John A Kosteva; Christine A Ciunci; Peter E Gabriel; Jeffrey C Thompson; Susan Stonehouse-Lee; Victoria E Sherry; Elizabeth Gilbert; Beth Eaby-Sandy; Faith Mutale; Gloria DiLullo; Roger B Cohen; Anil Vachani; Corey J Langer Journal: Lung Cancer Date: 2017-01-25 Impact factor: 5.705
Authors: Toni K Choueiri; David J Figueroa; André P Fay; Sabina Signoretti; Yuan Liu; Robert Gagnon; Keith Deen; Christopher Carpenter; Peter Benson; Thai H Ho; Lini Pandite; Paul de Souza; Thomas Powles; Robert J Motzer Journal: Clin Cancer Res Date: 2014-12-23 Impact factor: 12.531
Authors: Stéphane Chevrier; Jacob Harrison Levine; Vito Riccardo Tomaso Zanotelli; Karina Silina; Daniel Schulz; Marina Bacac; Carola Hermine Ries; Laurie Ailles; Michael Alexander Spencer Jewett; Holger Moch; Maries van den Broek; Christian Beisel; Michael Beda Stadler; Craig Gedye; Bernhard Reis; Dana Pe'er; Bernd Bodenmiller Journal: Cell Date: 2017-05-04 Impact factor: 41.582
Authors: Pooja Ghatalia; Jennifer Gordetsky; Fengshen Kuo; Essel Dulaimi; Kathy Q Cai; Karthik Devarajan; Sejong Bae; Gurudatta Naik; Timothy A Chan; Robert Uzzo; A Ari Hakimi; Guru Sonpavde; Elizabeth Plimack Journal: J Immunother Cancer Date: 2019-05-28 Impact factor: 13.751
Authors: Theresa Dornieden; Arne Sattler; Anna Pascual-Reguant; Annkathrin Helena Ruhm; Lion Gabriel Thiel; Yasmin Samira Bergmann; Linda Marie Laura Thole; Ralf Köhler; Anja Andrea Kühl; Anja Erika Hauser; Sengül Boral; Frank Friedersdorff; Katja Kotsch Journal: J Am Soc Nephrol Date: 2021-06-01 Impact factor: 14.978